Washington Report

Jan 09, 2015
Pharmaceutical Executive
Transparency, quality, collaboration key to filling pipelines, gaining reimbursement.
Dec 15, 2014
Pharmaceutical Executive
Foreign governments are enacting anti-fraud legislation as part of broader efforts to crack down on corrupt practices involving pharmaceutical companies and healthcare professionals.
Nov 01, 2014
Pharmaceutical Executive
Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge.
Aug 01, 2014
Pharmaceutical Executive
Tweeting limited, corrections okay, says FDA, as industry, regulators wrestle with the digital world. Our Washington Correspondent Jill Wechsler reports.
Jul 23, 2014
Pharmaceutical Executive
Pharma backs federal standards for compassionate use, drug importing, data transparency, and track-and-trace. Jill Wechsler reports.
Jun 16, 2014
Pharmaceutical Executive
Payers are seeking clear assessment of drug value to rationalize high drug prices. This issue has moved to center stage due to mounting concern over the high price for Gilead's Sovaldi, writes Jill Wechsler.
May 22, 2014
Pharmaceutical Executive
Despite provisions in the Affordable Care Act that require qualified health plans to cover 'basic' benefits, access to prescription drugs may be limited by high out-of-pocket costs and tight pharmacy management strategies.
Apr 10, 2014
Pharmaceutical Executive
Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.
Mar 01, 2014
Pharmaceutical Executive
Transparency initiatives are multiplying, affecting research, marketing and compliance.
Feb 01, 2014
Pharmaceutical Executive
Benefits offered by insurance plans on health exchanges and through Medicare are raising concerns about patient access to needed therapies, writes Jill Wechsler.
native1_300x100
lorem ipsum